In this study, researchers aimed to characterize cardiometabolic risk factors and cardiovascular disease incidence in racially and ethnically underrepresented women with breast cancer.

Investigators evaluated the benefit of leuprorelin immediately after radical prostatectomy for prostate cancer in patients with undetectable PSA levels.

Investigators explored the association between baseline patient-reported fatigue and the risk adverse events in cancer treatment trials.

In this retrospective cohort analysis, researchers aimed to identify key predictors of trial enrollment among cancer patients.

A survey of practices that treat AYA patients with cancer showed that almost half of them screen for financial hardship, but few offer cancer-specific navigation.

New CDC guidelines categorize childhood vaccinations into routine, high-risk, and shared clinical decision-making tiers.

A systematic review and meta-analysis compared the perioperative and oncologic outcomes of open versus minimally invasive inguinal lymphadenectomy during penile cancer surgery. A meta-analysis ...

The American Cancer Society’s Report on the Status of Cancer Disparities in the United States examines disparities in cancer occurrence and outcomes, and analyzes the factors that contribute to these ...

Ceralasertib is an oral selective inhibitor of the ATR kinase, an important DNA-repairing protein in tumor cells.

The Food and Drug Administration (FDA) has approved Rybrevant Faspro™, a subcutaneous (SC) formulation of amivantamab for all indications approved for the ...

In this systematic review and meta-analysis, researchers examined outcomes among advanced ovarian cancer patients who received interval debulking surgery compared to primary debulking surgery.

Lunsumio Velo is supplied as a ready-to-use, preservative-free solution in single-dose vials containing 5mg/0.5mL and 45mg/mL.